Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

Decisions 4th September 2018

Checked: not set yet by Next Review: not set yet

At the meeting on the 4th September the following decisions were agreed:

 

New Drug Requests

 

Approved

Paravit-CF

  • Approved for dietary management of Cystic Fibrosis patients

Otocomb Otic Ear ointment (unlicensed) and Synalar-N ointment

  • Approved for use in ENT clinic for patients with otitis externa or mastoid cavity infection. To be used after formulary ear drops. Synalar-N first line in clinic, otocomb otic ear ointment second line in clinic.

Not Approved 

Glycopyrronium

  • Not approved for drooling in Parkinson's disease patients. The group felt further information is required from applicant. Applicant has been invited to attend November meeting.

Shared Care Protocols/TLS change in status

Methotrexate IBD

  • Updated SCP approved

Ticagrelor 

  • Updated SCP approved pending clarification of monitoring of renal function after a month of initiation.

 Other

  • Enoxaparin biosimilars, Arovi® and Inhixa® to be added.